glp-1 receptor agonist pancreatitis risk meta-analysis Evaluating the Rates of and Pancreatic Cancer Among GLP‐1 Agonists: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials - Wen - 2025 - Endocrinology, Diabetes & Metabolism Risk of pancreatic cancer associated

Diabetes 62 , 15271536 (2013)

26 Future studies should track adolescent patients for at least 510 years to determine whether weight loss is sustainable and whether metabolic adaptations occur

works closely with patients to evaluate medical history, lifestyle factors, and treatment goals before recommending a GLP-1 therapy

The potential for more robust, structured nutrition and lifestyle therapy to mitigate weight gain following GLP-1 cessation has not been studied in controlled trials

Safety & Side Effects Most common side effects are mild and transient: Mild increase in heart rate Nausea Decreased appetite Constipation or diarrhoea Fatigue In many cases, mild side effects from the drug can be temporary

The review confirmed GLP-1R is expressed at high levels on -cells, where GLP-1 stimulates somatostatin secretion which in turn indirectly suppresses both glucagon and insulin through paracrine mechanisms